AB0377 Are co-morbidities during rheumatoid arthritis different from those in ankylosing spondyloarthritis ?

Background Patients with inflammatory rheumatic diseases are certainly not unscathed from a lot of comorbidities which may be due to the systemic inflammatory activity of rheumatic diseases themselves, immune dysfunction, or iatrogenic, they may also occur independently. Cardiovascular morbidity remains one of the most important to detect and is increased during these diseases. So are there significant differences between co-morbidities associated with rheumatoid arthritis (RA) and those with ankylosing spondyloarthritis (AS)? Objectives To highlight the difference between comorbidities in RA and AS. Methods This is a retrospective study of 111 patients followed for RA ACR 1987 criteria), and 60 patients followed for AS, compiled between January 2005 and December 2016. Results The mean age of patients with RA was 51.04 years [18–80 years] with a sex ratio (M/F) of 0.18. The average duration of disease progression was 6.54 years [0–29 years]. The mean age of patients with AS was 40.4 years [18–61] with a sex ratio (M/F) of 19. The average duration of disease progression was 16.8 years [1–45 years]. About cardiovascular comorbidities, 16.2% of patients with RA and 5.1% with AS were diagnosed with high blood pressure. Dyslipidemia was found in 2.7% of patients with RA and in 0% with AS. 31.5% with RA and 21.7% of AS have overweight and obesity was illustrated in 22.5% of RA and 11.7% of AS. Heart and coronary failure were documented in 5.4% of RA and 1.7% of AS. Likewise renal failure in 3,6% of RA and 3.4% of AS. Diabetes was found in 18% of RA and 10% of AS. Hypothyroidism in 5.4% of RA and 1.7% of AS. Gout attack in 0.9% of RA and 0% with AS and osteoporosis in 21.3% of RA and 40% of AS. Conclusions Our study concluded at the frequency of comorbidities and mostly cardiovascular in rheumatoid arthritis compared with AS. Osteoporosis is also more common in our studied population with RA, although not rare with our patients with AS. This can be explained by the prescription of corticosteroid therapy in RA. Disclosure of Interest None declared